Why are pulmonary drug delivery systems so important? And what is the industry state like?
Thank you for contacting ReportLinker and submitting your question.
This report published by BCC Research in May 2014 shows the state of the drug delivery system industry. It includes a full market analysis and forecast as well as detailing why pulmonary drug delivery systems are important. It looks at the current global market, gives information on available technologies, the benefits of pulmonary drug delivery systems as well as information on current inhalation drugs, asthma, chronic obstructive pulmonary disease and their markets.
The global market for pulmonary drug delivery technology was valued at $32.4 billion in 2013 and with a compound annual growth rate of 6.2%, it is expected to be worth $43.9 billion in 2018. The market for dry powder inhalers was worth $17.5 billion in 2013 and is expected to grow to $31.5 billion in 2018 with a CAGR of 12.5%. The nebulizer market was worth $685.7 million in 2013 and with a CAGR of 5.4%, it is expected to be worth $893.5 million in 2018.
The study provides a detailed overview and analysis of the present and future global market of pulmonary drug delivery technologies. The individual products are looked at in terms of their market and competitive environments, as well as their future prospects. It features a review of emerging technologies , with inhaled drug delivery systems being a major focus. The strengths, weaknesses, opportunities and threats of the market are also looked at.
Pulmonary drug delivery began as the most effective way of delivering drugs to the lungs, especially for conditions such as asthma, chronic obstructive pulmonary disease and emphysema. It is also now being used to deliver treatments for non-respiratory conditions such as diabetes and migraines. Current trends in the research and formulating sector include increased sales of dry powder inhalers, which are slowly replacing metered dose inhalers.
The report looks at global markets, new developments and forecasts trends through to 2018. It looks at market share by drug/device and drug and disease type, current products on the market, market share by company or product and statistical information on the prevalence of respiratory worldwide, with an emphasis on the U.S..
The information in the report is crucial for drug development companies as well as potential investors in this sector.
I hope you find this useful, and can see that there is a lot of useful information available through the portal about the pharmaceutical industry. If you have any additional needs or questions about our reports, please feel free to contact us.